The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Prostatic Neoplasms
  • Receptors, Interleukin-6
  • Transforming Growth Factor beta

abstract

  • We found that pretreatment plasma levels of IL6SR and TGF-beta1 improved the ability to predict biochemical progression by a prognostically substantial margin. A nomogram including the pretreatment levels of these molecular markers, along with standard clinical markers, has been developed and internally validated.

publication date

  • October 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2003.12.037

PubMed ID

  • 12913106

Additional Document Info

start page

  • 3573

end page

  • 9

volume

  • 21

number

  • 19